Kiniksa Pharmaceuticals International PLC
KNSA
查看详细走势图
42.000USD
-0.490-1.15%
收盘 12/26, 16:00（美东）报价延迟15分钟
3.17B总市值
86.36市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.15%
5天
0.00%
1月
-1.66%
6月
+47.99%
今年开始到现在
+112.34%
1年
+110.63%
查看详细走势图
TradingKey Kiniksa Pharmaceuticals International PLC股票评分
单位: USD 更新时间: 2025-12-24操作建议
Kiniksa Pharmaceuticals International PLC当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名11/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价54.00。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Kiniksa Pharmaceuticals International PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
54.000
目标均价
+29.96%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Kiniksa Pharmaceuticals International PLC亮点
亮点风险
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
业绩高增长
公司营业收入稳步增长，连续3年增长92.22%
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值87.37，处于3年历史高位
机构减仓
最新机构持股40.93M股，环比减少8.74%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值3.15K
活跃度降低
近期活跃度降低，过去20天平均换手率0.07
Kiniksa Pharmaceuticals International PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Kiniksa Pharmaceuticals International PLC简介
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
公司代码KNSA
公司Kiniksa Pharmaceuticals International PLC
CEOPatel (Sanjiv K)
网址https://www.kiniksa.com/
常见问题
Kiniksa Pharmaceuticals International PLC(KNSA)的当前股价是多少？
Kiniksa Pharmaceuticals International PLC(KNSA)的当前股价是 42.000。
Kiniksa Pharmaceuticals International PLC的股票代码是什么？
Kiniksa Pharmaceuticals International PLC的股票代码是KNSA。
Kiniksa Pharmaceuticals International PLC股票的52周最高点是多少？
Kiniksa Pharmaceuticals International PLC股票的52周最高点是44.420。
Kiniksa Pharmaceuticals International PLC股票的52周最低点是多少？
Kiniksa Pharmaceuticals International PLC股票的52周最低点是17.820。
Kiniksa Pharmaceuticals International PLC的市值是多少？
Kiniksa Pharmaceuticals International PLC的市值是3.17B。
Kiniksa Pharmaceuticals International PLC的净利润是多少？
Kiniksa Pharmaceuticals International PLC的净利润为-43.19M。
现在Kiniksa Pharmaceuticals International PLC(KNSA)的股票是买入、持有还是卖出？
根据分析师评级，Kiniksa Pharmaceuticals International PLC(KNSA)的总体评级为买入，目标价格为54.000。
Kiniksa Pharmaceuticals International PLC(KNSA)股票的每股收益（EPS TTM）是多少
Kiniksa Pharmaceuticals International PLC(KNSA)股票的每股收益（EPS TTM）是0.486。
相关品种
